MX2024004874A - Compuestos heterociclicos para uso en el tratamiento de cancer. - Google Patents

Compuestos heterociclicos para uso en el tratamiento de cancer.

Info

Publication number
MX2024004874A
MX2024004874A MX2024004874A MX2024004874A MX2024004874A MX 2024004874 A MX2024004874 A MX 2024004874A MX 2024004874 A MX2024004874 A MX 2024004874A MX 2024004874 A MX2024004874 A MX 2024004874A MX 2024004874 A MX2024004874 A MX 2024004874A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
heterocyclic compounds
derivatives
heterocyclic
Prior art date
Application number
MX2024004874A
Other languages
English (en)
Spanish (es)
Inventor
Robert Heald
Martin Stockley
Harry Finch
Owen Davis
Sam Mann
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Publication of MX2024004874A publication Critical patent/MX2024004874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004874A 2021-10-21 2022-10-21 Compuestos heterociclicos para uso en el tratamiento de cancer. MX2024004874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024004874A true MX2024004874A (es) 2024-05-06

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004874A MX2024004874A (es) 2021-10-21 2022-10-21 Compuestos heterociclicos para uso en el tratamiento de cancer.

Country Status (24)

Country Link
US (2) US20240425511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419527A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539132A (cg-RX-API-DMAC7.html)
KR (1) KR20240099274A (cg-RX-API-DMAC7.html)
CN (2) CN119053600A (cg-RX-API-DMAC7.html)
AR (1) AR127431A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022374050A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233255A1 (cg-RX-API-DMAC7.html)
DK (1) DK4419526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008687T3 (cg-RX-API-DMAC7.html)
FI (1) FI4419526T3 (cg-RX-API-DMAC7.html)
GB (1) GB202115156D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070568T2 (cg-RX-API-DMAC7.html)
IL (1) IL311922A (cg-RX-API-DMAC7.html)
LT (1) LT4419526T (cg-RX-API-DMAC7.html)
MX (1) MX2024004874A (cg-RX-API-DMAC7.html)
PL (1) PL4419526T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419526T (cg-RX-API-DMAC7.html)
RS (1) RS66620B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419526T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500123T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334150A (cg-RX-API-DMAC7.html)
WO (2) WO2023067355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115158D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115150D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds

Also Published As

Publication number Publication date
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
SMT202500123T1 (it) 2025-05-12
EP4419526A1 (en) 2024-08-28
LT4419526T (lt) 2025-03-25
CN119053600A (zh) 2024-11-29
TW202334150A (zh) 2023-09-01
RS66620B1 (sr) 2025-04-30
AU2022374050A1 (en) 2024-05-02
JP2024542949A (ja) 2024-11-19
WO2023067356A1 (en) 2023-04-27
PL4419526T3 (pl) 2025-04-22
US20240425511A1 (en) 2024-12-26
EP4419526B1 (en) 2024-12-25
EP4419527A1 (en) 2024-08-28
HUE070568T2 (hu) 2025-06-28
WO2023067355A1 (en) 2023-04-27
KR20240099274A (ko) 2024-06-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
DK4419526T3 (da) 2025-02-17
PT4419526T (pt) 2025-02-03
US20260124214A1 (en) 2026-05-07
FI4419526T3 (fi) 2025-02-13
AR127431A1 (es) 2024-01-24
HRP20250334T1 (hr) 2025-06-06
GB202115156D0 (en) 2021-12-08
IL311922A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2023013998A (es) Derivados de triazina y su uso en el tratamiento del cancer.
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MY199730A (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
NZ747313A (en) Imidazolone compounds as human neutrophil elastase inhibitors
PH12022551371A1 (en) Macrocycles for use in treating disease
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.